niacinamide has been researched along with Osteogenic Sarcoma in 16 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results of previous study showed promising but short-lived activity of sorafenib in the treatment of patients with unresectable advanced and metastatic osteosarcoma." | 9.20 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. ( Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A, 2015) |
| "This is the first report of activity achieved by the combination of the tyrosine kinase inhibitor sorafenib and the RANKL inhibitor denosumab in a patient with osteosarcoma." | 7.81 | RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward? ( Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R, 2015) |
| "The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma." | 7.79 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. ( Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E, 2013) |
| "The phytoalexin resveratrol has been described to have chemopreventive and chemotherapeutic effects in several tumor models while its effects on osteosarcoma have not been extensively studied." | 7.75 | Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. ( Bäckesjö, CM; Haldosén, LA; Li, Y; Lindgren, U, 2009) |
| "Sorafenib was reduced or briefly interrupted in 16 (46%) patients and permanently discontinued in one (3%) case due to toxicity." | 6.77 | A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. ( Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y, 2012) |
| "Osteosarcoma is a rare but aggressive bone neoplasm in humans, which is commonly treated with surgery, classical chemotherapy and radiation." | 5.40 | Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. ( Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B, 2014) |
| "Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs." | 5.35 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. ( Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B, 2009) |
| "Results of previous study showed promising but short-lived activity of sorafenib in the treatment of patients with unresectable advanced and metastatic osteosarcoma." | 5.20 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. ( Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A, 2015) |
| " Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR-34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A." | 3.85 | Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. ( DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q, 2017) |
| "This is the first report of activity achieved by the combination of the tyrosine kinase inhibitor sorafenib and the RANKL inhibitor denosumab in a patient with osteosarcoma." | 3.81 | RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward? ( Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R, 2015) |
| " In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed." | 3.81 | Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. ( Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J, 2015) |
| "The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma." | 3.79 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. ( Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E, 2013) |
| "The phytoalexin resveratrol has been described to have chemopreventive and chemotherapeutic effects in several tumor models while its effects on osteosarcoma have not been extensively studied." | 3.75 | Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. ( Bäckesjö, CM; Haldosén, LA; Li, Y; Lindgren, U, 2009) |
| "Sorafenib was reduced or briefly interrupted in 16 (46%) patients and permanently discontinued in one (3%) case due to toxicity." | 2.77 | A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. ( Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y, 2012) |
| "The osteosarcoma was only partially sensitive to the molecular-targeting drug sorafenib, which did not arrest its growth." | 1.46 | Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. ( Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M, 2017) |
| "Osteosarcoma is a rare but aggressive bone neoplasm in humans, which is commonly treated with surgery, classical chemotherapy and radiation." | 1.40 | Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. ( Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B, 2014) |
| "Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs." | 1.35 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. ( Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Giordano, G | 1 |
| Merlini, A | 1 |
| Ferrero, G | 1 |
| Mesiano, G | 1 |
| Fiorino, E | 1 |
| Brusco, S | 1 |
| Centomo, ML | 1 |
| Leuci, V | 1 |
| D'Ambrosio, L | 4 |
| Aglietta, M | 5 |
| Sangiolo, D | 3 |
| Grignani, G | 5 |
| Pignochino, Y | 5 |
| Jian, C | 1 |
| Tu, MJ | 1 |
| Ho, PY | 1 |
| Duan, Z | 1 |
| Zhang, Q | 1 |
| Qiu, JX | 1 |
| DeVere White, RW | 1 |
| Wun, T | 1 |
| Lara, PN | 1 |
| Lam, KS | 1 |
| Yu, AX | 1 |
| Yu, AM | 1 |
| Dell'Aglio, C | 1 |
| Basiricò, M | 1 |
| Capozzi, F | 2 |
| Soster, M | 1 |
| Marchiò, S | 1 |
| Bruno, S | 2 |
| Gammaitoni, L | 2 |
| Torchiaro, E | 1 |
| Fagioli, F | 4 |
| Ferrari, S | 4 |
| Alberghini, M | 2 |
| Picci, P | 4 |
| Walter, I | 2 |
| Wolfesberger, B | 2 |
| Miller, I | 1 |
| Mair, G | 1 |
| Burger, S | 1 |
| Gallè, B | 1 |
| Steinborn, R | 1 |
| Palmerini, E | 2 |
| Ferraresi, V | 1 |
| Bertulli, R | 1 |
| Asaftei, SD | 2 |
| Tamburini, A | 1 |
| Marchesi, E | 1 |
| Biagini, R | 1 |
| Gambarotti, M | 1 |
| Casali, PG | 2 |
| Cathomas, R | 1 |
| Rothermundt, C | 1 |
| Bode, B | 1 |
| Fuchs, B | 1 |
| von Moos, R | 1 |
| Schwitter, M | 1 |
| Yang, Q | 1 |
| Zhang, S | 1 |
| Kang, M | 1 |
| Dong, R | 1 |
| Zhao, J | 1 |
| Interiano, RB | 1 |
| McCarville, MB | 1 |
| Wu, J | 1 |
| Davidoff, AM | 1 |
| Sandoval, J | 1 |
| Navid, F | 1 |
| Hu, Y | 1 |
| Bobb, D | 1 |
| He, J | 1 |
| Hill, DA | 1 |
| Dome, JS | 1 |
| Yılmaz, S | 1 |
| Özçakar, ZB | 1 |
| Taktak, A | 1 |
| Kiremitçi, S | 1 |
| Ensari, A | 1 |
| Dinçaslan, H | 1 |
| Yalçınkaya, F | 1 |
| Murakami, T | 1 |
| Igarashi, K | 1 |
| Kawaguchi, K | 1 |
| Kiyuna, T | 1 |
| Zhang, Y | 1 |
| Zhao, M | 1 |
| Hiroshima, Y | 1 |
| Nelson, SD | 1 |
| Dry, SM | 1 |
| Li, Y | 2 |
| Yanagawa, J | 1 |
| Russell, T | 1 |
| Federman, N | 1 |
| Singh, A | 1 |
| Elliott, I | 1 |
| Matsuyama, R | 1 |
| Chishima, T | 1 |
| Tanaka, K | 1 |
| Endo, I | 1 |
| Eilber, FC | 1 |
| Hoffman, RM | 1 |
| Bäckesjö, CM | 1 |
| Haldosén, LA | 1 |
| Lindgren, U | 1 |
| Tonar, Z | 1 |
| Gerner, W | 1 |
| Skalicky, M | 1 |
| Heiduschka, G | 1 |
| Egerbacher, M | 1 |
| Thalhammer, JG | 1 |
| Cavalloni, G | 1 |
| Motta, M | 1 |
| Tapparo, M | 1 |
| Bottos, A | 1 |
| Migliardi, G | 1 |
| Camussi, G | 1 |
| Torchio, B | 1 |
| Bussolino, F | 1 |
| Dileo, P | 1 |
| Mercuri, M | 1 |
| Han, XR | 1 |
| Sun, Y | 1 |
| Bai, XZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma[NCT01804374] | Phase 2 | 38 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Osteogenic Sarcoma
| Article | Year |
|---|---|
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi | 2015 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi | 2015 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi | 2015 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progressi | 2015 |
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neop | 2012 |
14 other studies available for niacinamide and Osteogenic Sarcoma
| Article | Year |
|---|---|
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cell Line, Tumor; Chondrosarcoma; Comput | 2021 |
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Ther | 2017 |
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B | 2013 |
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Ant | 2014 |
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2015 |
Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2015 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Fe | 2015 |
The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzoquinones; Cell Line, Tumor; Cell Pr | 2015 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2016 |
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neo | 2017 |
Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells.
Topics: Anticarcinogenic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship | 2009 |
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bone Neoplasms; Caspase 3; Cell Count; | 2010 |
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytos | 2009 |
The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Screening As | 2012 |